New Research Highlights Cost-Effectiveness of Menopausal Hormone Therapy
Menopausal hormone therapy (MHT) has faced scrutiny for decades, largely due to concerns raised by the Women's Health Initiative study in 2002, which associated hormone therapy with increased risks of blood clots, stroke, and breast cancer. As a result, the uptake of MHT has significantly declined, with only about 4% to 5% of eligible women in the U.S. currently using it, compared to around 40% before the study's findings were published. However, new research published in Obstetrics & Gynecology challenges this narrative by modeling the cost-effectiveness of MHT specifically for 50-year-old women experiencing moderate to severe menopausal symptoms such as hot flashes and night sweats.
This analysis indicates that MHT not only improves health outcomes but also saves money. The researchers compared the lifetime costs of women using MHT to those who did not. They focused on two common forms of MHT delivered through the skin: transdermal estradiol alone and transdermal estradiol combined with micronized progesterone. The findings revealed that, over a lifetime, women using estradiol alone would incur costs that are approximately $13,540 less than those who do not receive treatment, while those using the combination therapy would save about $12,773. Both treatment options were associated with an increase of 3.3 quality-adjusted life years per woman, which measures both the length and quality of life.
When scaled to a hypothetical group of 10,000 women, the total lifetime healthcare spending for those not receiving MHT was estimated at $1.48 billion, compared to about $1.35 billion for those receiving MHT. On a national level, if the estimated 15.9 million American women aged 50 to 59 who qualify for treatment were to adopt MHT, the projected savings could reach approximately $216 billion.
Interestingly, the primary driver of these financial savings was found to be cardiovascular protection rather than symptom relief. Dr. Jill Brown, the lead researcher and vice chair of gynecologic surgery and obstetrics at the Uniformed Services University, emphasized that cardiovascular disease is the leading cause of death among women, making the cardiovascular benefits of MHT particularly relevant.
As estrogen levels decline during menopause, women face increased cardiovascular risks, including changes in body composition and lipid levels, which can lead to heart disease. The protective role of estrogen underscores the importance of starting MHT closer to the onset of menopause.
In addition to cardiovascular benefits, the research also noted reductions in hip fractures and overall mortality among women using MHT compared to those who did not. Estrogen's role in maintaining bone density is well-documented, and its decline post-menopause significantly increases fracture risk.
While the symptom relief provided by MHT is crucial—affecting roughly 80% of menopausal women, with about 25% experiencing severe symptoms—this research indicates that the broader health benefits of MHT should not be overlooked. The financial implications of MHT extend beyond the cost of the therapy itself, which is relatively modest compared to the expenses associated with treating heart disease or hip fractures.
The analysis conducted by the researchers involved simulations based on published cost and risk estimates, suggesting that MHT is both a cost-effective and beneficial intervention for women starting treatment around age 50. Nevertheless, it is important to recognize that MHT may not be suitable for every woman. Individual risk factors and personal health histories should be discussed with healthcare providers to determine the best course of action. This research provides valuable data for women considering MHT, allowing them to engage in informed discussions with their clinicians about their health and treatment options.




